ArticleUpdates in surgery2026
Microsatellite instability and immunotherapy: redefining the role of surgery in colorectal cancer.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The integration of molecular diagnostics into surgical oncology is redefining the management of colorectal cancer (CRC). Microsatellite instability (MSI) testing and mismatch repair (MMR) analysis have moved from purely prognostic tools to key determinants of therapeutic strategy. In MSI-high (MSI-H) and MMR-deficient (dMMR) tumours, immune checkpoint inhibitors have shown unprecedented pathological response rates, leading to a paradigm shift in non-metastatic CRC. Recently published trials suggest that immunotherapy may alter the timing and extent of resection, while raising new questions about patient selection, surgical planning, and long-term oncological safety. Conversely, microsatellite-stable (MSS) disease remains a therapeutic frontier, with ongoing studies exploring combined immunotherapy regimens. This evolving landscape demands that surgeons develop a deeper understanding of tumour biology and participate actively in translational research. The future of CRC surgery will rely not only on technical excellence but on the ability to integrate molecular knowledge into precise, multidisciplinary treatment algorithms.
Indexed as
Identifiers
41507458What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.